Sugi Predict

Sugi Predict / Targets / SSTR5

SSTR5

Somatostatin receptor type 5 · P35346 · SSTR5 on Sugi Atlas →

42,617 patent compounds predicted against SSTR5, 24,962 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL299979 SCHEMBL299979 1.00 20/20
SCHEMBL669591 SCHEMBL669591 1.00 20/20
SCHEMBL669853 SCHEMBL669853 1.00 20/20
SCHEMBL669960 SCHEMBL669960 1.00 20/20
SCHEMBL669977 SCHEMBL669977 1.00 20/20
SCHEMBL670132 SCHEMBL670132 1.00 20/20
SCHEMBL670133 SCHEMBL670133 1.00 20/20
SCHEMBL670366 SCHEMBL670366 1.00 20/20
SCHEMBL670385 SCHEMBL670385 1.00 20/20
SCHEMBL670459 SCHEMBL670459 1.00 20/20
SCHEMBL670468 SCHEMBL670468 1.00 20/20
SCHEMBL670607 SCHEMBL670607 1.00 20/20
SCHEMBL670768 SCHEMBL670768 1.00 20/20
SCHEMBL670838 SCHEMBL670838 1.00 20/20
SCHEMBL671019 SCHEMBL671019 1.00 20/20
SCHEMBL671086 SCHEMBL671086 1.00 20/20
SCHEMBL671089 SCHEMBL671089 1.00 20/20
SCHEMBL671180 SCHEMBL671180 1.00 20/20
SCHEMBL671186 SCHEMBL671186 1.00 20/20
SCHEMBL671203 SCHEMBL671203 1.00 20/20

Clinical trials — most relevant to SSTR5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pasireotide Treatment for Neuroendocrine Tumor PHASE4WITHDRAWN
Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour PHASE3COMPLETED
Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer PHASE2COMPLETED
Pasireotide LAR in Severe Polycystic Liver Disease PHASE2COMPLETED
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide PHASE1/PHASE2RECRUITING
Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression PHASE2UNKNOWN
Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression PHASE2COMPLETED
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors PHASE1/PHASE2RECRUITING
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors PHASE1/PHASE2RECRUITING
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor PHASE2RECRUITING
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake PHASE2RECRUITING
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours PHASE2RECRUITING
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors PHASE1/PHASE2COMPLETED
An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours PHASE2UNKNOWN
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). PHASE1/PHASE2RECRUITING
Early Feasibility Study of Somatostatin Receptors PET Imaging for the Diagnosis of Infective Endocarditis PHASE2COMPLETED
Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors PHASE1/PHASE2COMPLETED
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer PHASE2COMPLETED
61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET) PHASE1/PHASE2RECRUITING
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas PHASE1/PHASE2WITHDRAWN
Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study PHASE2COMPLETED
Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms EARLY_PHASE1COMPLETED
Molecular and Whole-body MR Imaging in Lymphomas nanCOMPLETED
Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia nanNO_LONGER_AVAILABLE
Observational Study on GEP-and Pulm-NET Treated at FPG nanRECRUITING
Epidemiology of Acromegaly in Denmark 1991-2010 nanUNKNOWN
Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT) nanNOT_YET_RECRUITING
CardioNETPOL National Registry of Carcinoid Heart Disease nanNOT_YET_RECRUITING
Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin Resistance nanCOMPLETED
The Role of 68GA DOTATATE PET/CT In Breast Cancer Imaging nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SSTR5 binder may also engage these)

ProteinNameSimilarity
P30938 — 0.990 P30938 →
SSTR4 Somatostatin receptor type 4 0.989 landscape →
F1MV99 — 0.989 F1MV99 →
O08858 — 0.987 O08858 →
P30937 — 0.983 P30937 →
P49660 — 0.979 P49660 →
Q49LX5 — 0.975 Q49LX5 →
SSTR1 Somatostatin receptor type 1 0.971 landscape →
SSTR3 Somatostatin receptor type 3 0.970 landscape →
P30873 — 0.969 P30873 →
P28646 — 0.967 P28646 →
P49681 — 0.965 P49681 →
Q56UD9 — 0.965 Q56UD9 →
Q8MJV3 — 0.962 Q8MJV3 →
NPBWR1 Neuropeptides B/W receptor type 1 0.960 landscape →
P33533 — 0.957 P33533 →
P48146 — 0.956 P48146 →
P30936 — 0.956 P30936 →
OPRD1 Delta-type opioid receptor 0.954 landscape →
P32300 — 0.953 P32300 →
P30935 — 0.952 P30935 →
MLNR Motilin receptor 0.947 landscape →
NPFFR1 Neuropeptide FF receptor 1 0.944 landscape →
P56481 — 0.939 P56481 →
Q9BDQ5 — 0.938 Q9BDQ5 →
P30796 — 0.938 P30796 →
P79292 — 0.938 P79292 →
P30552 — 0.938 P30552 →
P2RY2 P2Y purinoceptor 2 0.937 landscape →
LTB4R Leukotriene B4 receptor 1 0.937 landscape →